...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

NovAliX Signs Multiyear Services Agreement for Chemistry

| Print |
Monday, 28 February 2011 11:25 (UTC + 1)

NovAliX_Logo

Strasbourg, France, February 28, 2011 / b3c newswire /NovAlix today announces that it has entered into a multi-year research services agreement for chemistry with Janssen-Cilag, France, to support its drug discovery efforts.

 

Under the terms, NovAliX scientists will provide distant as well on-site chemistry support, optimally exploiting strong organic synthetic expertise and unique biophysical capabilities, to accelerate the drug discovery process. In addition the operational excellence of NovAliX allows to explore a complete new model by which the respective scientists work side by side for greater efficiency and scientific exchange and therefore promoting the concept of Open Innovation.

 

Stephan Jenn, president of NovAliX, said "he welcomes this significant chemistry discovery deal that acknowledges the quality of our science, technologies and organization".

 


About NovAliX SAS - www.novalix-pharma.com

Strasbourg, France based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing.

 

With proprietary unique SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.

 

NovAliX Group, a team of 120 scientists, is located in state-of-the-art laboratory facilities in Strasbourg-Illkirch (France) and Heidelberg (Germany)

 


Contact
Stephan Jenn
President
Bld Sébastien Brant, BP 30170
NovAliX
F-67405 Illkirch CEDEX FRANCE
Phone : +33 368 330 200
This e-mail address is being protected from spambots. You need JavaScript enabled to view it